Trial Profile
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 11 Aug 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 11 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Dec 2009 New trial record